세계의 약독 생백신 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Live Attenuated Vaccines Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

US $ 3,920 ￦ 5,614,000

PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 4,730 ￦ 6,774,000

PDF & Excel (10-user License)

PDF 및 Excel 보고서를 동일 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 7,430 ￦ 10,641,000

PDF & Excel (Corporate User License)

PDF 및 Excel 보고서를 동일 기업 내 모든 사용자가 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

한글목차

세계의 약독 생백신 시장은 큰 성장을 이루어 시장 규모는 2024년 212억 3,000만 달러에서 2033년에는 529억 1,000만 달러로 급증할 전망이며, 예측 기간 중 연평균 복합 성장률(CAGR) 10.68%로 견조한 성장을 보일 것으로 예측됩니다.

세계의 약독 생백신 시장은 예방접종 프로그램 증가와 감염증에 대한 효과적이고 장기적인 면역력에 대한 수요에 견인되어 견조한 성장을 이룰 것으로 예측됩니다. 유전공학과 바이러스 벡터 기술의 개발은 보다 안전하고 표적화된 약독 생백신의 개발을 가능하게 하고 있습니다. 향후 기술 혁신은 사용 편의성과 컴플라이언스를 향상시키기 위해 내열성 제형과 바늘을 사용하지 않는 전달 시스템에 초점을 맞출 것으로 보입니다.

또한 COVID-19 팬데믹은 백신 연구와 생산 능력 확대를 가속화하고 있습니다. 신흥 시장의 의식이 높아지고 정부의 대처로 백신 접종률이 확대되고 있습니다. 규제의 조화와 관민 파트너십은 시장 진입과 유통을 촉진합니다. 세계 보건 위생 우선 순위가 진화함에 따라 약독 생백신 시장은 혁신을 계속하고 안전하고 효과적이며 사용하기 쉬운 예방 접종 솔루션을 제공할 것입니다.

목차

제1장 서문

제2장 주요 요약

• 시장의 하이라이트
• 세계 시장 현황

제3장 약독 생백신 : 산업 분석

• 서문 : 시장 역학
• 시장 성장 촉진요인
• 시장 성장 억제요인
• 기회
• 업계 동향
• Porter's Five Forces 분석
• 시장 매력 분석

제4장 밸류체인 분석

• 밸류체인 분석
• 원재료 분석
  • 원재료 리스트
  • 원재료 제조업체 리스트
  • 주요 원재료의 가격 동향
• 잠재적 구매자 목록
• 마케팅 채널
  • 직접 마케팅
  • 간접 마케팅
  • 마케팅 채널 발전 동향

제5장 세계의 약독 생백신 시장 분석 : 백신 유형별

• 개요 : 백신 유형별
• 과거 및 예측 데이터 분석 : 백신 유형별
• 세균 백신
• 바이러스 백신

제6장 세계의 약독 생백신 시장 분석 : 개발별

• 개요 : 개발별
• 과거 및 예측 데이터 분석 : 개발별
• 조직 배양
• 배화란
• 살아있는 동물

제7장 세계의 약독 생백신 시장 분석 : 투여 방식별

• 개요 : 투여 방식별
• 과거 및 예측 데이터 분석 : 투여 방식별
• 경구
• 주사제
• 경비

제8장 세계의 약독 생백신 시장 분석 : 연령층별

• 개요 : 연령층별
• 과거 및 예측 데이터 분석 : 연령층별
• 소아
• 성인

제9장 세계의 약독 생백신 시장 분석 : 적응증별

• 개요 : 적응증별
• 과거 및 예측 데이터 분석 : 적응증별
• 결핵
• 홍역
• 로타바이러스
• 황열
• 경구 소아마비
• 인플루엔자
• 기타 적응증

제10장 세계의 약독 생백신 시장 분석 : 최종 용도별

• 개요 : 최종 용도별
• 과거 및 예측 데이터 분석 : 최종 용도별
• 병원(공립, 사립)
• 전문 클리닉
• 기타 최종 사용자

제11장 세계의 약독 생백신 시장 분석 : 지역별

• 지역별 전망
• 서문
• 북미의 매출 분석
  • 개요, 분석 및 예측
  • 북미 : 부문별
  • 북미 국가별
  • 미국
  • 캐나다
  • 멕시코
• 유럽의 매출 분석
  • 개요, 분석 및 예측
  • 유럽 : 부문별
  • 유럽 국가별
  • 영국
  • 프랑스
  • 독일
  • 이탈리아
  • 러시아
  • 기타 유럽
• 아시아태평양의 매출 분석
  • 개요, 분석 및 예측
  • 아시아태평양 : 부문별
  • 아시아태평양 국가별
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주
  • 동남아시아
  • 기타 아시아태평양
• 라틴아메리카의 매출 분석
  • 개요, 분석 및 예측
  • 라틴아메리카 : 부문별
  • 라틴아메리카 국가별
  • 브라질
  • 아르헨티나
  • 페루
  • 칠레
  • 기타 라틴아메리카
• 중동 및 아프리카의 매출 분석
  • 개요, 분석 및 예측
  • 중동 및 아프리카 : 부문별
  • 중동 및 아프리카 국가별 일람
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 이스라엘
  • 남아프리카
  • 기타 중동 및 아프리카

제12장 약독 생백신 기업 경쟁 구도

• 약독 생백신 시장 경쟁
• 파트너십, 제휴 및 협정
• 합병 및 인수
• 신제품 출시
• 기타 개발

제13장 기업 프로파일

• 주요 기업의 시장 점유율 분석
• 시장 집중도
• Abbott
• Bharat Biotech International Limited
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline Plc
• Haffkine Biopharmaceutical Corporation Limited
• HBI
• Merck & Co.
• Novartis Pharmaceuticals Corporation
• Sanofi
• Serum Institute Of India Ltd.
• Valneva SE
• Zydus Group

AJY

영문 목차

영문목차

Global Live Attenuated Vaccines Market is poised for a significant growth, with market size projected to surge from USD 21.23 Billion in 2024 to USD 52.91 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 10.68% during the forecast period.

The global live attenuated vaccines market is set for robust growth driven by increasing immunization programs and demand for effective, long-lasting immunity against infectious diseases. Advances in genetic engineering and viral vector technologies are enabling development of safer, more targeted live attenuated vaccines. Future innovations will focus on thermostable formulations and needle-free delivery systems to improve accessibility and compliance.

Moreover, the COVID-19 pandemic has accelerated vaccine research and manufacturing capacity expansion. Growing awareness and government initiatives in emerging markets are expanding vaccination coverage. Regulatory harmonization and public-private partnerships are facilitating market entry and distribution. As global health priorities evolve, the live attenuated vaccines market will continue to innovate, delivering safe, efficacious, and accessible immunization solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Live Attenuated Vaccines market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Vaccine Type

• Bacterial Vaccine
• Viral Vaccine

By Development

• Tissue Culture
• Embryonated Eggs
• Live Animals

By Mode Of Administration

• Oral
• Injectable
• Intranasal

By Age Group

• Pediatric
• Adult

By Indication

• Tuberculosis
• Measles
• Rotavirus
• Yellow Fever
• Oral Polio
• Influenza
• Other Indications

By End-Use

• Hospitals (Public, Private)
• Specialty Clinics
• Other End-Users
• List of Companies Profiled in the report
• Abbott, Bharat Biotech International Limited, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Haffkine Biopharmaceutical Corporation Limited, HBI, Merck & Co., Novartis Pharmaceuticals Corporation, Sanofi, Serum Institute of India Ltd., Valneva SE, Zydus Group.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. LIVE ATTENUATED VACCINES - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Vaccine Type
  • 3.7.2 Market Attractiveness Analysis By Development
  • 3.7.3 Market Attractiveness Analysis By Mode Of Administration
  • 3.7.4 Market Attractiveness Analysis By Age Group
  • 3.7.5 Market Attractiveness Analysis By Indication
  • 3.7.6 Market Attractiveness Analysis By End-Use
  • 3.7.7 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY VACCINE TYPE

• 5.1. Overview By Vaccine Type
• 5.2. Historical and Forecast Data Analysis By Vaccine Type
• 5.3. Bacterial Vaccine Historic and Forecast Sales By Regions
• 5.4. Viral Vaccine Historic and Forecast Sales By Regions

6. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY DEVELOPMENT

• 6.1. Overview By Development
• 6.2. Historical and Forecast Data Analysis By Development
• 6.3. Tissue Culture Historic and Forecast Sales By Regions
• 6.4. Embryonated Eggs Historic and Forecast Sales By Regions
• 6.5. Live Animals Historic and Forecast Sales By Regions

7. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY MODE OF ADMINISTRATION

• 7.1. Overview By Mode Of Administration
• 7.2. Historical and Forecast Data Analysis By Mode Of Administration
• 7.3. Oral Historic and Forecast Sales By Regions
• 7.4. Injectable Historic and Forecast Sales By Regions
• 7.5. Intranasal Historic and Forecast Sales By Regions

8. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY AGE GROUP

• 8.1. Overview By Age Group
• 8.2. Historical and Forecast Data Analysis By Age Group
• 8.3. Pediatric Historic and Forecast Sales By Regions
• 8.4. Adult Historic and Forecast Sales By Regions

9. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY INDICATION

• 9.1. Overview By Indication
• 9.2. Historical and Forecast Data Analysis By Indication
• 9.3. Tuberculosis Historic and Forecast Sales By Regions
• 9.4. Measles Historic and Forecast Sales By Regions
• 9.5. Rotavirus Historic and Forecast Sales By Regions
• 9.6. Yellow Fever Historic and Forecast Sales By Regions
• 9.7. Oral Polio Historic and Forecast Sales By Regions
• 9.8. Influenza Historic and Forecast Sales By Regions
• 9.9. Other Indications Historic and Forecast Sales By Regions

10. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY END-USE

• 10.1. Overview By End-Use
• 10.2. Historical and Forecast Data Analysis By End-Use
• 10.3. Hospitals (Public, Private) Historic and Forecast Sales By Regions
• 10.4. Specialty Clinics Historic and Forecast Sales By Regions
• 10.5. Other End-Users Historic and Forecast Sales By Regions

11. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY GEOGRAPHY

• 11.1. Regional Outlook
• 11.2. Introduction
• 11.3. North America Sales Analysis
  • 11.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 11.3.2 North America By Segment Sales Analysis
  • 11.3.3 North America By Country Sales Analysis
  • 11.3.4 United States Sales Analysis
  • 11.3.5 Canada Sales Analysis
  • 11.3.6 Mexico Sales Analysis
• 11.4. Europe Sales Analysis
  • 11.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 11.4.2 Europe By Segment Sales Analysis
  • 11.4.3 Europe By Country Sales Analysis
  • 11.4.4 United Kingdom Sales Analysis
  • 11.4.5 France Sales Analysis
  • 11.4.6 Germany Sales Analysis
  • 11.4.7 Italy Sales Analysis
  • 11.4.8 Russia Sales Analysis
  • 11.4.9 Rest Of Europe Sales Analysis
• 11.5. Asia Pacific Sales Analysis
  • 11.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 11.5.2 Asia Pacific By Segment Sales Analysis
  • 11.5.3 Asia Pacific By Country Sales Analysis
  • 11.5.4 China Sales Analysis
  • 11.5.5 India Sales Analysis
  • 11.5.6 Japan Sales Analysis
  • 11.5.7 South Korea Sales Analysis
  • 11.5.8 Australia Sales Analysis
  • 11.5.9 South East Asia Sales Analysis
  • 11.5.10 Rest Of Asia Pacific Sales Analysis
• 11.6. Latin America Sales Analysis
  • 11.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 11.6.2 Latin America By Segment Sales Analysis
  • 11.6.3 Latin America By Country Sales Analysis
  • 11.6.4 Brazil Sales Analysis
  • 11.6.5 Argentina Sales Analysis
  • 11.6.6 Peru Sales Analysis
  • 11.6.7 Chile Sales Analysis
  • 11.6.8 Rest of Latin America Sales Analysis
• 11.7. Middle East & Africa Sales Analysis
  • 11.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 11.7.2 Middle East & Africa By Segment Sales Analysis
  • 11.7.3 Middle East & Africa By Country Sales Analysis
  • 11.7.4 Saudi Arabia Sales Analysis
  • 11.7.5 UAE Sales Analysis
  • 11.7.6 Israel Sales Analysis
  • 11.7.7 South Africa Sales Analysis
  • 11.7.8 Rest Of Middle East And Africa Sales Analysis

12. COMPETITIVE LANDSCAPE OF THE LIVE ATTENUATED VACCINES COMPANIES

• 12.1. Live Attenuated Vaccines Market Competition
• 12.2. Partnership/Collaboration/Agreement
• 12.3. Merger And Acquisitions
• 12.4. New Product Launch
• 12.5. Other Developments

13. COMPANY PROFILES OF LIVE ATTENUATED VACCINES INDUSTRY

• 13.1. Top Companies Market Share Analysis
• 13.2. Market Concentration Rate
• 13.3. Abbott
  • 13.3.1 Company Overview
  • 13.3.2 Company Revenue
  • 13.3.3 Products
  • 13.3.4 Recent Developments
• 13.4. Bharat Biotech International Limited
  • 13.4.1 Company Overview
  • 13.4.2 Company Revenue
  • 13.4.3 Products
  • 13.4.4 Recent Developments
• 13.5. Boehringer Ingelheim International GmbH
  • 13.5.1 Company Overview
  • 13.5.2 Company Revenue
  • 13.5.3 Products
  • 13.5.4 Recent Developments
• 13.6. GlaxoSmithKline Plc
  • 13.6.1 Company Overview
  • 13.6.2 Company Revenue
  • 13.6.3 Products
  • 13.6.4 Recent Developments
• 13.7. Haffkine Biopharmaceutical Corporation Limited
  • 13.7.1 Company Overview
  • 13.7.2 Company Revenue
  • 13.7.3 Products
  • 13.7.4 Recent Developments
• 13.8. HBI
  • 13.8.1 Company Overview
  • 13.8.2 Company Revenue
  • 13.8.3 Products
  • 13.8.4 Recent Developments
• 13.9. Merck & Co.
  • 13.9.1 Company Overview
  • 13.9.2 Company Revenue
  • 13.9.3 Products
  • 13.9.4 Recent Developments
• 13.10. Novartis Pharmaceuticals Corporation
  • 13.10.1 Company Overview
  • 13.10.2 Company Revenue
  • 13.10.3 Products
  • 13.10.4 Recent Developments
• 13.11. Sanofi
  • 13.11.1 Company Overview
  • 13.11.2 Company Revenue
  • 13.11.3 Products
  • 13.11.4 Recent Developments
• 13.12. Serum Institute Of India Ltd.
  • 13.12.1 Company Overview
  • 13.12.2 Company Revenue
  • 13.12.3 Products
  • 13.12.4 Recent Developments
• 13.13. Valneva SE
  • 13.13.1 Company Overview
  • 13.13.2 Company Revenue
  • 13.13.3 Products
  • 13.13.4 Recent Developments
• 13.14. Zydus Group
  • 13.14.1 Company Overview
  • 13.14.2 Company Revenue
  • 13.14.3 Products
  • 13.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies

관련자료